0001209191-21-021585.txt : 20210317 0001209191-21-021585.hdr.sgml : 20210317 20210317200305 ACCESSION NUMBER: 0001209191-21-021585 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210315 FILED AS OF DATE: 20210317 DATE AS OF CHANGE: 20210317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Riker Lauren Bullaro CENTRAL INDEX KEY: 0001545439 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 21752521 MAIL ADDRESS: STREET 1: C/O PACIRA PHARMACEUTICALS, INC. STREET 2: 5 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-15 0 0001396814 Pacira BioSciences, Inc. PCRX 0001545439 Riker Lauren Bullaro C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Vice President, Finance Common Stock 2021-03-15 4 M 0 1520 10.81 A 14701 D Common Stock 2021-03-15 4 S 0 1520 73.28 D 13181 D Common Stock 2021-03-17 4 M 0 2000 10.81 A 15181 D Common Stock 2021-03-17 4 S 0 2000 70.01 D 13181 D Stock Option (Right to Buy) 10.81 2021-03-15 4 M 0 1520 0.00 D 2022-06-05 Common Stock 1520 16300 D Stock Option (Right to Buy) 10.81 2021-03-17 4 M 0 2000 0.00 D 2022-06-05 Common Stock 2000 14300 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.03 to $73.50, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $70.04, inclusive. The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. /s/ Kristen Williams, Attorney-in-Fact 2021-03-17